Minerva claims 'positive' PhII data on depression drug while skeptics push stock down
It might have come in a bit of an unorthodox shape, but Minerva Neurosciences says it has a Phase II win in its hands.
When measured against the bar of a 2-sided type I error level of 0.1, the biotech said, one of three tested doses of its depression drug seltorexant passes muster for a statistically significant improvement over placebo. In their words:
The least squares mean (LS mean) difference from placebo of the change in [Montgomery-Asberg Depression Rating Scale] total score at the end of week 6 was 3.1 for the 20 mg dose of seltorexant, and the 2-sided p-value was 0.083, which is below the pre-specified 2-sided type I error level of 0.1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
